A61K 40/4261
Proteoglycans
Official title: {Proteoglycans, e.g. glypican, brevican or CSPG4}
A61K40/4261 (Proteoglycans) appears on 63 US grants and 238 published applications in this corpus.
Search patents in A61K- Granted patents
- 63
- Published applications
- 238
- Assignees
- 139
- Inventors
- 554
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 5 |
| 2017 | 0 | 4 |
| 2018 | 2 | 9 |
| 2019 | 0 | 9 |
| 2020 | 6 | 13 |
| 2021 | 2 | 26 |
| 2022 | 6 | 27 |
| 2023 | 11 | 39 |
| 2024 | 14 | 52 |
| 2025 | 9 | 29 |
| 2026 | 12 | 22 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Methods and compositions for chimeric antigen receptor targeting cancer cells1 Sep 2026US 12,721,892 B2The University of North Carolina at Chapel Hill
- Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment18 Aug 2026US 12,709,737 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Anti-glypican-1-immunizing antigen receptor4 Aug 2026US 12,698,339 B2Iwate Medical University
- Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors4 Aug 2026US 12,698,340 B2Adicet Therapeutics, Inc.
- Car-t cell compositions, methods of use thereof1 Oct 2026US 2026/0297160 A1Augusta University Research Institute, Inc.
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
- Chimeric antigen receptor and application thereof3 Sep 2026US 2026/0256914 A1Guangzhou Reforgene Medicine Co., Ltd.
- Gene-edited natural killer cells27 Aug 2026US 2026/0250634 A1Crispr Therapeutics AG
- Gpc3 binding molecules20 Aug 2026US 2026/0242507 A1Kite Pharma, Inc.
Most cited
By later US patents
- Modified NK-92 cells for treating cancer13US 10,738,279 B2NantKwest, Inc. · 2020
- Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof5US 10,822,413 B2Eureka Therapeutics, Inc. · 2020
- T cell compositions5US 11,479,755 B22seventy bio, Inc. · 2022
- Chimeric antigen receptor-modified NK-92 cells5US 11,547,727 B2ImmunityBio, Inc. · 2023
- Chimeric antigen receptors targeting GPC3 and uses thereof4US 10,731,127 B2Carsgen Therapeutics Co., Ltd. · 2020